Search Results

You are looking at 1 - 10 of 380 items for :

  • Refine by Access: All x
Clear All
Full access

Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives

John M. Salsman, Steven M. Grunberg, Jennifer L. Beaumont, Miriam Rogers, Diane Paul, Marla L. Clayman, and David Cella

Nausea and vomiting are two of the most common and debilitating side-effects of chemotherapy and can result in significant morbidity and adversely impact patient quality of life. 1 – 4 Nausea and vomiting secondary to chemotherapy may lead to

Full access

Biobehavioral Factors in Chemotherapy-Induced Nausea and Vomiting

Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, and Abhay R. Shelke

and Prochlorperazine in patients with chemotherapy-induced nausea and vomiting . N Engl J Med 1981 ; 305 : 905 – 909 . 3 Morrow GR Roscoe JA Hickok JT . Nausea and Vomiting . In: Holland JC. , ed. Psycho-oncology. New York : Oxford

Full access

Radiation-Induced Nausea and Vomiting

Susan Urba

Radiat Oncol Bio Phys 1999 ; 44 : 619 – 625 . 3. Horiot JC . Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting? Int J Radiat Oncol Biol Phys 2004 ; 15 : 1018 – 1025 . 4

Full access

Behavioral Interventions in Treating Anticipatory Nausea and Vomiting

Colmar Figueroa-Moseley, Pascal Jean-Pierre, Joseph A. Roscoe, Julie L. Ryan, Sadhna Kohli, Oxana G. Palesh, Elizabeth P. Ryan, Jennifer Carroll, and Gary R. Morrow

The authors have been supported by Grant U10CA 37420 from the National Cancer Institute. References 1. Osoba D Zee B Warr D . Effect of postchemotherapy nausea and vomiting on health-related quality of life . The Quality of

Full access

Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting

Barbara Todaro

The management of chemotherapy-induced nausea and vomiting (CINV) has improved over the past 20 years. Before the introduction of 5-hydroxytryptamine (5-HT3) receptor antagonists, treatment options were limited to less-effective and more

Full access

Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting

Sally Yowell Barbour

agents associated with high rates of CINV Analyze the use of corticosteroids in the treatment of acute CINV Analyze the use of corticosteroids in the treatment of delayed CINV Chemotherapy-induced nausea and vomiting (CINV) is one of the most

Full access

Use of Acupuncture in the Control of Chemotherapy-Induced Nausea and Vomiting

Ting Bao

cancer nausea and vomiting . J Clin Oncol 2008 ; 26 : 3903 – 3910 . 2 Hickok JT Roscoe JA Morrow GR . Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of

Full access

BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin

Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou, and Rudolph M. Navari

department (ED) events (IP/ED) as “potentially avoidable” if involving any of 10 toxicities, including nausea or vomiting (NV). Evidence demonstrates meaningful gaps in oncologists’ adherence to antiemetic prophylaxis guidelines for highly emetogenic

Full access

Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia

Presented by: Eunice S. Wang

; GI, gastrointestinal; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; N/V, nausea and vomiting; R/R, relapse/refractory; TKI, tyrosine kinase inhibitor. Targeting IDH Mutations IDH mutations are found much less frequently

Full access

BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)

Rudolph M. Navari, Erminio Bonizzoni, Rita Wickham, and Rebecca Clark-Snow

2-4. Inclusion/exclusion criteria were similar across studies. Data from the 3 studies were pooled for efficacy endpoints of: 1) complete response (CR: no emesis, no rescue medication); 2) no significant nausea (NSN: max <25 mm on 100 mm VAS); and 3